Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Today's news is very good. CBMG will run up to over $10 soon. More buyers coming in. I hold on long with lose. Hope to make even soon.
Hey.....You were right.
First of all they have to give us an update on the situation with WIEI in which CBMG has over 2 million shares.
China IPO now is hot, but esatbridge guys stop IPO job where are they?
Sounds sensible.....But no, they will probably continue with the same old garbage, protecting "their" pockets, entitling themselves to "bonus" shares, for a job well done, and continue the ways of a SCAM company.....
You do know, this is just a SCAM?.....(don't you?).....
Shouldn't they be applying for a higher exchange soon.
It certainly can steer northward, on minimal volume.....
What it lacks is volume(or interest)....
Good golly....
12 hours per week, for 150k per year.
I must have done something wrong in my life....
Wish I could turn back the hands of time....
LOL.
FORM 8-K FILED: Change In Directors Or Principal Officers
http://biz.yahoo.com/e/140507/cbmg8-k.html
Apparently, that's old news....
I think they've completely left that "stuff", in light of the new "bio" stuff.....
(actually, I'm happy if it just holds its value, regardless of what their "fancy" is....)
LOL
Has any one heard anything about the Eastbridge side of the company?
What happen to all those companies and dividends they has in the works?
Your welcome,
Concerning the position here:
One concern. Is EBIG division dead, no real news or income since the merger. What happen to all those companies they had in the pipeline?
Big boom if it going to occur it will be 4th quarter this year. This is when they are suppose to have Knee osteoarthritis product on the market.
True......As in, grow gray hairs waiting.
Someday soon, this company will put out some news.
There will be a brief awakening.....Then it will go back to sleep.
Of all the microcaps and penny stocks I own, this has got to be the slowest one.....Record breaking sluggish.....
Finally got around to it...
Fidelity said yes, they will process paperwork(certificate), and I should see results in 15-20 days...
Apparently, it was my responsibility to call them, about the affair. Otherwise nothing would have ever happened...
Live and learn.
Thanks for the heads up.
How did you make out with Fidelity
Same thing happened to me. $1500 just arrived in my account and when I contacted TD I was told that my Tsingda shares had been purchased by the company.
oct 24,2013 $2.30 a share
Never happened for me. Maybe they hope certain shareholders have died, and won't ever question anything.....
Can I ask how long ago that was, and what you got per share for payout? I'm wondering if it's worth the hassle....Thanks.
You might want to check with Fidelity and Norm Klein, I have a TD Ameritrade account, Tsingda purchased back my shares with out notifying me.
Heck no. They still sit in my fidelity account, as restricted shares. I think I remember you, or somebody, speculating that they would be "paid out". Never happened. Tsingda never completed IPO. So, they are valueless. Same thing with Wonder shares, only they did go public, and have dropped in value, to worthless....To turn the Wonder shares into tradeable status, would cost an arm and a leg....Anybody else out there, see it any different?
rich
Didn't you get paid for your tsingda shares.
How old?
I'm still riding ancient shares, and still in "the plus"...
As far as wiei and tsingda, those are a lost cause...
I'm still hoping for some eventual mini-peak here, with typically swinelike news, and I'll sell....
Same slime bags own ARPC and WIEI. These are all Chinese controlled fake companies with no business. I am screwed because of my old shares now trading so low.
This is a long hold stock, not a trading stock.
WIEI 10-Q out!!! CBMG owns 2.5 million shares of WIEI.
http://www.sec.gov/Archives/edgar/data/1456137/000138713113004372/wieig-10q_093013.htm
WIEI is extremely undervalued. CBMG should benefit greatly from any asset appreciation of WIEI.
Yes, $5 soon is very possible. The public float must be getting locked up pretty quick by investors like you and I with only 900,000 shares in public float for WIEI...not much to go around. 1 week from today we will see 3rd quarter results, excited for that. Most investors don't realize they have the $40 million "passive stake" on the books (7% ownership) from their ownership in China Wonder. I see this as $40 million in cash on the books. Add this fact to the operating income and cash they generate from operations and low debt on the books and we have a gem here.
Word just needs to get out to investment community and get a little interest brewing and we will roar higher. My guess some people are shying away from WIEI a little bit because WIEI is thinly traded. Not a stock to trade but rather accumulate and be patient, in my opinion
Good news!
Cellular Biomedicine Group Announces New Product Approved for Market in China and New Exclusive License
Date : 10/30/2013 @ 9:01AM
Source : PR Newswire (US)
Stock : Cellular Biomedicine Group, Inc. (QB) (CBMG)
Quote : 5.9 0.8 (15.69%) @ 2:46PM
Cellular Biomedicine Group Announces New Product Approved for Market in China and New Exclusive License
PrintAlert
Cellular Biomedicine Group, Inc. (QB) (USOTC:CBMG)
Intraday Stock Chart
Today : Wednesday 30 October 2013
PALO ALTO, Calif., Oct. 30, 2013 /PRNewswire/ -- Today Cellular Biomedicine Group (OTCQB:CBMG) announced that their A-Stromal™ adipose stromal cell purification kit is ready to launch on the market in China. In addition, they have signed an exclusive China and Hong Long license for ProCeller computer controlled processing system to extract stem cells from adipose tissue. These two products, when used together, allow for safe and contaminant-free isolation of one million Vascular Stromal Cells per 1 mL of adipose tissue in as little as sixty minutes. The potential clients for both products are cosmetic clinics, research institutions, sports medicine departments and veterinarian clinics.
About A-Stromal™
The A-Stromal™ kit was developed completely in-house by Cellular Biomedicine Group, Inc. and is covered by two China patents. The China Food and Drug Administration (CFDA) approved this kit as a medical device and it is the first certified product of its kind in China. It contains all critical reagents and material to purify Vascular Stromal Cells (VSC) or Stromal Vascular Fraction (SVF) from adipose (fat) tissue and includes detailed instructions for use and hands-on training.
Dr. William Cao, CEO of Cellular Biomedicine Group, Inc., explained, "The proprietary protocols of the A-Stromal™ kit provide a high concentration of VSC, averaging one million VSC cells per 1 mL of adipose tissue, with greater than 90% cell viability. This allows the doctor to extract a very small amount of adipose tissue from the patient in order to isolate enough VSC required for a therapeutic or cosmetic procedure."
The A-Stromal™ kits will be manufactured in Cellular Biomedicine Group's cGMP-certified facility in Wuxi, China, which has been approved by the CFDA as a manufacturing facility for Medical Devices and is accredited ISO (International Standards Organization) 9001:2008 certification by internationally recognized quality management system SGS.
About ProCeller
Cellular Biomedicine Group HK, Ltd. (a subsidiary of Cellular Biomedicine Group, Inc.) has signed an exclusive license for the China and Hong Kong market with Dr. Hsu-Wei Fang, whose team holds the China patent and Taiwan patent for ProCeller, which is CE-marked. Dr. Fang is a Professor of the Department of Chemical Engineering and Biotechnology of National Taipei University of Technology (Taipei Tech) and brought ProCeller to the Taiwan market over two years ago.
ProCeller is an integrated, all-in-one computerized platform that offers a miniature cleanroom environment to isolate cells. The single piece of equipment is composed of a temperature controlled orbital shaker, integrated vacuum system, integrated centrifuge and HEPA filtered, self-sterilizing environment. It is a user-friendly interface with step-by-step procedures displayed on an LED screen.
"The advantage of the ProCeller equipment," stated Dr. Fang, "is that normally a hospital or clinic would have to dedicate a significant amount of space within the clinic and purchase several pieces of costly equipment and raw materials in order to build their own cleanroom facility to process cells. The ProCeller machine is one integrated piece of equipment that takes up a relatively small amount of space and requires minimal training."
ProCeller has been designed to meet the demands of many clinical and research applications, including isolation of VSC and SVF, purifying fat for lipotransfer in cosmetic surgery, isolating peripheral blood monocytes for immunological study, and separating platelet-rich plasma (PRP) for regenerative medicine use.
Dr. Cao commented, "We are proud to present ProCeller and A-Stromal™ kit as the first integrated system for fat cell processing to the Greater China market."
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.
Contact:
Sarah Kelly
Director of Corporate Communications, CBMG
+1 650 566 5064
sarah.kelly@cellbiomedgroup.com
SOURCE Cellular Biomedicine Group
Copyright 2013 PR Newswire
Today's new is excellent for CBMG, but how about listing business is going? Any one know?
Yahoo message board has come down, I suspect this one will be used more often now.
CBMG fact sheet
http://cellbiomedgroup.com/CBMGfact-sheet%2002-2013.pdf
Sadly, they've removed the list. I think it's because they never quite acomplished anything worthwhile, in the dividend/distribution arena, even though it was their "quest" for I think almost ten years now. The only one I believe got finished, was Wonder. It of course went through an IPO, then just slowly went downward to its present low PPS. I think some here(like me) own a few restricted shares, but because of the fees involved in getting them tradeable, they'll probably never amount to anything good. The only other one distrbuted was Tsingda shares, which remain restricted, awaiting an IPO that will probaly never happen(I think due to "Wonder shock"). The rest of the list, never amounted to a hill of beans, and I believe they will remain that way, forever.
Sorry to sound so negative, but their history of bringing companies to a listed state and distributing shares, is a bleak one at best.
There's a small list of the companies they "entertained" over time, lower down on the intro information here, under "clients".
I believe their current(and possibly only) "active" interest, is in the biomedicine thing.
Correct me if I'm wrong, any of you out there. I haven't listened in on any of the conference calls, for about two years now.
Hi All
Wondering whether anyone can help me. I am trying to find a list of the stock dividends declared (and distributed by EBIG). There used to be a list on the website but since the merger it has all been replaced by a link to the CBMG website.
Many thanks,
Smivs
Low float for WIEI is reason for no volume...20 million outstanding shares and about 19 million locked up by insiders/management. When he moves, she will move big. WIEI is a $5-10 stock. It might take an uplisting to a higher exchange (which management said was the plan awhile back in conference call), but the key here is to be patient.
If WIEI financials are great why there is no volume at all and the asking bid is $0.10 only :(
Huge day for WIEI...great financials!!!
LOL you are right. Golfing in shareholders cash. That is a quick rich plan
It's what is known as a "do nothing" company.
I'm sorry.....
They do do something.....
They golf.
Cut and Run ppl!! What a joke of a volume 400!!
It's not me. It's could be insider. I am still under water. Only want to get money back soon.
You must be trying to sell a big block of 8K. Someone is putting their shares up for sale, and you appear to be the only person talking.
CBMG is ready to take off to over $10, Good news could be out soon.
Probably golfing......
Followers
|
35
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2750
|
Created
|
05/17/07
|
Type
|
Free
|
Moderators |
Cellular Biomedicine Group (NASDAQ: CBMG) is a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. We are the result of the acquisition, transfer, commercialization and advancement of thirty years of research and human treatment experience in cellular medicine. Our cellular research and development comes from collaboration among scientists and doctors from the US, Europe and China.
MARKET
Our primary target market is Greater China. Our first two therapy candidates are currently used to treat patients in research studies conducted in China. We are also engaged in a number of pre-clinical studies for other product or therapy candidates, which we believe have the potential to become safe and effective treatment options for a variety of degenerative and debilitating conditions. We believe that the results of our research studies will support expanded preclinical and clinical trials with a larger population of patients, which we expect to carry out through authorized treatment centers throughout Greater China. With the recent acquisition of AG, we added technical services revenue comprised of T Cells Receptor (“TCR”) clonality analysis technology and T Central Memory Cell (“Tcm”) and Dendritic Cell (“DC”) preparation methodologies.
Indication: Knee Osteoarthritis (KOA)
Technology Platform: Human Adipose-Derived Mesenchymal Progenitor Cells (haMPC)
Trial Phase: Clinical Trial Phase IIb, all patients completed treatment as of August 2014
Interim results from phase IIb clinical trial for KOA: klick here
Osteoarthritis is a degenerative disease of the joints. KOA is one of the most common types of osteoarthritis. Pathological manifestation of osteoarthritis is primarily local inflammation caused by immune response and subsequent damage of joints. Restoration of immune response and joint tissues are the objective of therapies.
According to International Journal of Rheumatic Diseases, 2011, 53% of KOA patients will degenerate to the point of disability. Conventional treatment usually involves invasive surgery with painful recovery and physical therapy. As drug-based methods of management are ineffective, the same journal estimates that some 1.5 million patients with this disability will degenerate to the point of requiring artificial joint replacement surgery every year. However, only 40,000 patients will actually be able to undergo replacement surgery, leaving the majority of patients to suffer from a life-long disability due to lack of effective treatment.
About haMPCs
haMPCs are currently being considered as a new and effective treatment for osteoarthritis, with a huge potential market. Osteoarthritis is one of the ten most disabling diseases in developed countries. Worldwide estimates are that 9.6% of men and 18.0% of women aged over 60 years have symptomatic osteoarthritis. It is estimated that the global OA therapeutics market was worth $4.4 billion in 2010 and is forecast to grow at a compound annual growth rate (“CAGR”) of 3.8% to reach $5.9 billion by 2018.
In order to bring haMPC-based KOA therapy to market, our market strategy is to: (a) establish regional laboratories that comply with cGMP standards in Shanghai and Beijing that meet Chinese regulatory approval; and (b) file joint applications with Class AAA hospitals (own commentary: press release from 09.02.2015 (klick here): We look forward to working with PLAGH as a long-term partner as we evaluate paths to commercialization,” commented Dr. William (Wei) Cao, Chief Executive Officer of Cellular Biomedicine Group.) to use haMPCs to treat KOA in a clinical trial setting.
Our KOA therapy is not surgically invasive – it uses a small amount (30ml) of adipose tissue obtained via liposuction from the patient, which is cultured and re-injected into the patient. The injections are designed to induce the body’s secretion of growth factors promoting immune response and regulation, and regrowth of cartilage. The down-regulation of the patient’s immune response is aimed at reducing and controlling inflammation which is a central cause of KOA.
We believe our proprietary method, subsequent haMPC proliferation and processing know-how will enable haMPC therapy to be a low cost and relatively safe and effective treatment for KOA. Additionally, banked haMPCs can continue to be stored for additional use in the future.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |